Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NMS-03597812 |
Synonyms | |
Therapy Description |
NMS-03597812 inhibits PERK, potentially leading to apoptosis of tumor cells and decreased tumor growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NMS-03597812 | NMS 03597812|NMS03597812 | NMS-03597812 inhibits PERK, potentially leading to apoptosis of tumor cells and decreased tumor growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06549790 | Phase I | NMS-03597812 | Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05027594 | Phase I | Dexamethasone + NMS-03597812 NMS-03597812 | Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma | Terminated | USA | 0 |